Results 11 to 20 of about 131 (88)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).

PLoS Neglected Tropical Diseases, 2021
The four dengue virus serotypes (DENV1-4) infect several hundred million people each year living in tropical and sub-tropical regions. Clinical development of DENV vaccines is difficult because immunity to a single serotype increases risk of severe ...
Laura J White, Ellen F Young, Mark J Stoops, Sandra R Henein, Elizabeth C Adams, Ralph S Baric, Aravinda M de Silva   +6 more
doaj   +4 more sources

Reply to: Letter to Editor “Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine”

Expert Review of Vaccines
Zeb Youard
exaly   +5 more sources

Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.

PLoS Medicine
BackgroundDengue is an increasing global problem associated with negative health and economic impacts. Vaccination is an important measure to reduce the significant public health and economic burden caused by dengue.
Jing Shen, Elizaveta Kharitonova, Anna Tytula, Justyna Zawieja, Samuel Aballea, Shibadas Biswal, Mayuri Sharma, Supattra Rungmaitree, Rosarin Sruamsiri, Derek Wallace, Riona Hanley   +10 more
doaj   +4 more sources

Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003 [PDF]

Frontiers in Immunology, 2019
The development of an efficacious DENV vaccine has been a long-standing public health priority. However, this effort has been complicated significantly due to the hazard presented by incomplete humoral immunity in mediating immune enhancement of ...
Adam T. Waickman, Heather Friberg, Morgan Gargulak, Amanda Kong, Mark Polhemus, Timothy Endy, Stephen J. Thomas, Richard G. Jarman, Jeffrey R. Currier   +8 more
doaj   +3 more sources

Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial

Vaccine
Exploring time-to-onset of efficacy of the live-attenuated dengue vaccine TAK-003 is important for individuals living in, or traveling to, dengue-endemic areas. This protocol-defined exploratory analysis of the Tetravalent Immunization against Dengue Efficacy Study (TIDES) investigated TAK-003's onset of efficacy after the first and before the second ...
Shibadas Biswal, Vianney Tricou, Nicolas Folschweiller   +2 more
exaly   +3 more sources

The Tolerability of the Dengue Vaccine TAK-003 (Qdenga^®) in German Travelers: The Results of a Prospective Survey

Tropical Medicine and Infectious Disease
Background: The global incidence of dengue has markedly increased over the last decades. Consequently, the risk of infection has increased significantly, resulting in record numbers of imported cases in various European countries and elsewhere in 2024 ...
Tomas Jelinek, Juliane Kramm, Maik Wagner, Claudia Jelinek   +3 more
doaj   +4 more sources

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination

Journal of Infectious Diseases
Abstract Background We explored the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on the efficacy of Takeda's dengue vaccine candidate, TAK-003. Methods Children 4–16 years of age were randomized 2:1 to ...
Astrid Borkowski, Eduardo López-Medina, Charissa Borja-Tabora   +2 more
exaly   +3 more sources

Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine

Vaccine
The tetravalent dengue vaccine TAK-003 and the 9-valent human papillomavirus (9vHPV) vaccine regimens are potentially compatible, with overlapping target age groups, facilitating inclusion of TAK-003 into established immunization programs.This phase 3, open-label, randomized, multicenter trial was conducted in Thailand to investigate the immunogenicity
Tarek, El Hindi, Suvaporn, Anugulruengkitt, Keswadee, Lapphra, Kriengsak, Limkittikul, Auchara, Tangsathapornpong, Claudia, Galindo-Tsoukas, Michael, Hellwig, Nicholas, Roubinis, Ron, Schuring, Shibadas, Biswal, Nicolas, Folschweiller   +10 more
exaly   +3 more sources

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003) [PDF]

Clinical Infectious Diseases, 2021
Abstract Background Takeda’s live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety in both seronegative and seropositive participants and that its ...
Rivera, Luis, Biswal, Shibadas, Sáez-Llorens, Xavier, Reynales, Humberto, López-Medina, Eduardo, Borja-Tabora, Charissa, Bravo, Lulu, Sirivichayakul, Chukiat, Kosalaraksa, Pope, Martinez Vargas, Luis, Yu, Delia, Watanaveeradej, Veerachai, Espinoza, Felix, Dietze, Reynaldo, Fernando, LakKumar, Wickramasinghe, Pujitha, Duarte MoreiraJr, Edson, Fernando, Asvini D, Gunasekera, Dulanie, Luz, Kleber, Venâncioda Cunha, Rivaldo, Rauscher, Martina, Zent, Olaf, Liu, Mengya, Hoffman, Elaine, LeFevre, Inge, Tricou, Vianney, Wallace, Derek, Alera, MariaTheresa, Borkowski, Astrid   +29 more
openaire   +2 more sources

GRADE 3 SOLICITED AND UNSOLICITED ADVERSE EVENTS (AES) FOLLOWING VACCINATION WITH TAKEDA'S TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003)

International Journal of Infectious Diseases, 2023
Intro: An ongoing, long-term phase 3 trial (NCT02747927) in eight dengue- endemic countries is evaluating Takeda's dengue vaccine candidate, TAK-003.
E. Ismail, V. Tricou, N. Folschweiller, E. Lloyd, M. Rauscher, S. Biswal   +5 more
doaj   +1 more source